Oncternal Therapeutics Stock Return On Asset
| ONCTDelisted Stock | USD 0.53 0.00 0.00% |
Oncternal Therapeutics fundamentals help investors to digest information that contributes to Oncternal Therapeutics' financial success or failures. It also enables traders to predict the movement of Oncternal Stock. The fundamental analysis module provides a way to measure Oncternal Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncternal Therapeutics stock.
Oncternal |
Oncternal Therapeutics Company Return On Asset Analysis
Oncternal Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Oncternal Therapeutics Return On Asset | -0.76 |
Most of Oncternal Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncternal Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
CompetitionBased on the latest financial disclosure, Oncternal Therapeutics has a Return On Asset of -0.7645. This is 91.26% lower than that of the Biotechnology sector and 96.76% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Oncternal Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncternal Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncternal Therapeutics could also be used in its relative valuation, which is a method of valuing Oncternal Therapeutics by comparing valuation metrics of similar companies.Oncternal Therapeutics is currently under evaluation in return on asset category among its peers.
Oncternal Fundamentals
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (17.57) % | ||||
| Current Valuation | (12.83 M) | ||||
| Shares Outstanding | 2.96 M | ||||
| Shares Owned By Insiders | 9.23 % | ||||
| Shares Owned By Institutions | 12.07 % | ||||
| Number Of Shares Shorted | 14.21 K | ||||
| Price To Earning | (37.77) X | ||||
| Price To Book | 0.17 X | ||||
| Price To Sales | 0.72 X | ||||
| Revenue | 785 K | ||||
| Gross Profit | (31.49 M) | ||||
| EBITDA | 2.23 M | ||||
| Net Income | (39.48 M) | ||||
| Cash And Equivalents | 78.9 M | ||||
| Cash Per Share | 1.48 X | ||||
| Total Debt | 318 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 10.78 X | ||||
| Book Value Per Share | 3.09 X | ||||
| Cash Flow From Operations | (32.16 M) | ||||
| Short Ratio | 0.09 X | ||||
| Earnings Per Share | (11.69) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 27 | ||||
| Beta | 1.33 | ||||
| Market Capitalization | 1.56 M | ||||
| Total Asset | 36.73 M | ||||
| Retained Earnings | (197.78 M) | ||||
| Working Capital | 30.86 M | ||||
| Current Asset | 27.27 M | ||||
| Current Liabilities | 6.3 M | ||||
| Net Asset | 36.73 M |
About Oncternal Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncternal Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncternal Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncternal Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Oncternal Stock
If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |